Approximately 12,000 people will be diagnosed with a soft-tissue sarcoma in the United States this year. Currently, there are few treatment options available, especially for tumors that grow or spread to other parts of the body during treatment. However, recent research has shown that the chemotherapy eribulin (Halaven) may be a promising new treatment option for people with two types of rare soft-tissue sarcomas: leiomyosarcoma and adipocytic sarcoma, which is also called liposarcoma.
According to the results of a recent study, people who have surgery to remove lymph nodes near a melanoma tumor live the same amount of time as those who are watched closely for signs of cancer.
A recent study shows that adding docetaxel (Docefrez, Taxotere) chemotherapy to the standard treatment of hormone therapy and radiation therapy helps men with high-risk, localized prostate cancer live longer.
In an ongoing study, researchers found that adding a new targeted therapy to chemotherapy controls non-Hodgkin lymphoma (NHL) growth for more than twice as long as only chemotherapy.
A recent study showed that the drug pacritinib works better for myelofibrosis than current treatments.
In a large, ongoing study, researchers found that a combination of ibrutinib (Imbruvica) and standard treatment slows the growth of chronic lymphocytic leukemia (CLL) and lowers patients’ risk of dying from the disease.
A phase III clinical trial has shown that nivolumab (Opdivo) is an effective treatment option for people with non-squamous, non-small cell lung cancer (NSCLC).
Results from a phase I clinical trial show that pembrolizumab (Keytruda) is able to shrink head and neck cancer that has spread to other parts of the body or come back after treatment. These findings suggest that immunotherapy may fill a large unmet need for better treatments for recurrent and advanced head and neck cancer.
In an early-stage study, nivolumab (Opdivo) has shown encouraging results as a treatment for advanced liver cancer. Liver cancer is the leading cause of cancer deaths worldwide, accounting for more than 600,000 deaths each year. People diagnosed with advanced liver cancer especially need new treatment options, as there is currently only one drug approved by the U.S. Food and Drug Administration (FDA).
Results from a small phase II study suggest that the PD-1 immunotherapy, pembrolizumab (Keytruda), works better when tumors have a large number of genetic changes or mutations.